EVOLVE Short DAPT Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2009 participants.
Also called NCT02605447
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,009 participants
- Sponsor
- Registry
-
NCT02605447
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Germany, Japan, Latvia, Sweden, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT02605447. Allocation not applicable; no masking; primary purpose treatment. Start 2016-02-16 (actual); primary completion 2019-07-17 (actual). Results posted on 2020-09-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EVOLVE Short DAPT Study
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- 3 months of dual antiplatelet therapy (DAPT)
- Intervention (Device)
- SYNERGY Stent System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct02605447- Content hash
ae24579deed40d3534d4eb27e2ff8ae5b841a8aab239f9b68c554c8eb5ab3336